Qlucore Receives Approval for EUR 0.5 Million EU Payment
17 juni, 20:30
Qlucore, a leading provider of software for precision cancer diagnostics, has received approval for a third payment of approximately EUR 0.5 million under its previously awarded EU grant. The total grant amounts to EUR 2.5 million and is distributed across four installments.
The project aims to accelerate the development of clinical cancer diagnostic solutions for acute myeloid leukemia (AML) and bladder cancer. Following successful progress and review within the agreed project timeline, the next installment is now approved for disbursement.
Over the course of the three-year project, Qlucore will develop and launch CE-marked software for clinical cancer diagnostics in AML and bladder cancer. The solutions are intended for use in clinical laboratories and will also support the development of companion diagnostics in collaboration with pharmaceutical partners.
AML and bladder cancer are areas of particular focus due to their complex RNA profiles. These RNA-based signatures offer significant potential to improve diagnostic accuracy and treatment selection. However, such molecular information is currently not fully utilized in clinical practice. The project aims to enable broader adoption of this data to support more precise, individualized treatment decisions.
Research-use-only versions of the tests for AML and bladder cancer have been available since April 2026 through Qlucore Insights.
For use in clinical diagnostics, software must comply with IVDR regulations and obtain CE marking. In this project, Qlucore builds on prior investments in Qlucore Diagnostics BCP-ALL, including both software capabilities and a certified quality management system. Qlucore Diagnostics BCP-ALL 1.0 was launched in February 2025 and is currently in use at clinical laboratories.
“This EU payment strengthens Qlucore financially and supports our continued progress in RNA-seq-based clinical diagnostics,” says Carl-Johan Ivarsson, CEO of Qlucore.
The initial target market includes clinical laboratories across Europe, followed by expansion into the U.S. market.
Certified Advisor
FNCA Sweden AB
Web: www.fnca.se
Contacts
Carl-Johan Ivarsson, CEO
Phone: +46 (0) 46 286 31 10
Email: carl-johan.ivarsson@qlucore.com
About Qlucore
Qlucore develops AI‑based software that enables more accurate diagnostics and a more cost‑efficient healthcare system. Through the company’s precision medicine solutions, tens of thousands of genetic data points are transformed into clear decision‑making support, making it possible to deliver the right treatment to each patient at the right time.
The first diagnostic test – for pediatric blood cancer – has been approved for sale within the EU. Additional tests, including for lung cancer, adult blood cancer, and bladder cancer, are under development. These products target large and growing markets with significant medical and economic needs. The goal is to improve treatment outcomes, reduce human suffering, and lower healthcare costs.
In addition to its diagnostics portfolio, Qlucore offers Qlucore Omics Explorer, an established software platform for advanced data analysis used by researchers and pharmaceutical companies worldwide. The company has customers in about 20 countries, sales offices in Europe and North America, and distributors across several Asian markets.
Qlucore is listed on Nasdaq First North Growth market. More information: www.qlucore.com
Ämnen i artikeln
Qlucore Receives Approval for EUR 0.5 Million EU Payment
17 juni, 20:30
Qlucore, a leading provider of software for precision cancer diagnostics, has received approval for a third payment of approximately EUR 0.5 million under its previously awarded EU grant. The total grant amounts to EUR 2.5 million and is distributed across four installments.
The project aims to accelerate the development of clinical cancer diagnostic solutions for acute myeloid leukemia (AML) and bladder cancer. Following successful progress and review within the agreed project timeline, the next installment is now approved for disbursement.
Over the course of the three-year project, Qlucore will develop and launch CE-marked software for clinical cancer diagnostics in AML and bladder cancer. The solutions are intended for use in clinical laboratories and will also support the development of companion diagnostics in collaboration with pharmaceutical partners.
AML and bladder cancer are areas of particular focus due to their complex RNA profiles. These RNA-based signatures offer significant potential to improve diagnostic accuracy and treatment selection. However, such molecular information is currently not fully utilized in clinical practice. The project aims to enable broader adoption of this data to support more precise, individualized treatment decisions.
Research-use-only versions of the tests for AML and bladder cancer have been available since April 2026 through Qlucore Insights.
For use in clinical diagnostics, software must comply with IVDR regulations and obtain CE marking. In this project, Qlucore builds on prior investments in Qlucore Diagnostics BCP-ALL, including both software capabilities and a certified quality management system. Qlucore Diagnostics BCP-ALL 1.0 was launched in February 2025 and is currently in use at clinical laboratories.
“This EU payment strengthens Qlucore financially and supports our continued progress in RNA-seq-based clinical diagnostics,” says Carl-Johan Ivarsson, CEO of Qlucore.
The initial target market includes clinical laboratories across Europe, followed by expansion into the U.S. market.
Certified Advisor
FNCA Sweden AB
Web: www.fnca.se
Contacts
Carl-Johan Ivarsson, CEO
Phone: +46 (0) 46 286 31 10
Email: carl-johan.ivarsson@qlucore.com
About Qlucore
Qlucore develops AI‑based software that enables more accurate diagnostics and a more cost‑efficient healthcare system. Through the company’s precision medicine solutions, tens of thousands of genetic data points are transformed into clear decision‑making support, making it possible to deliver the right treatment to each patient at the right time.
The first diagnostic test – for pediatric blood cancer – has been approved for sale within the EU. Additional tests, including for lung cancer, adult blood cancer, and bladder cancer, are under development. These products target large and growing markets with significant medical and economic needs. The goal is to improve treatment outcomes, reduce human suffering, and lower healthcare costs.
In addition to its diagnostics portfolio, Qlucore offers Qlucore Omics Explorer, an established software platform for advanced data analysis used by researchers and pharmaceutical companies worldwide. The company has customers in about 20 countries, sales offices in Europe and North America, and distributors across several Asian markets.
Qlucore is listed on Nasdaq First North Growth market. More information: www.qlucore.com
Ämnen i artikeln
Aktieanalys
Ekholms sorti
Styrräntan
Aktieanalys
Ekholms sorti
Styrräntan
Marknadsöversikt
1 DAG %
Senast
1 mån
